Company: MIRA
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001641172-25-024077
Chunk: 14

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Item 8
Chunk 14
---
 with third-party suppliers, manufacturers and other service providers and their ability to perform adequately;

    ●
    the
    potential market size, opportunity, and growth potential for our product candidates, if approved;

    ●
    our
    ability to obtain additional funding for our operations and development activities;

    ●
    the
    accuracy of our estimates regarding expenses, capital requirements and needs for additional financing;

    ●
    the
    initiation, timing, progress and results of our clinical studies and clinical trials, and our research and development programs;

    ●
    the
    timing of anticipated regulatory filings;

    ●
    the
    timing of availability of data from our clinical trials;

    ●
    our
    future expenses, capital requirements, need for additional financing, and the period over which we believe that our existing cash
    and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements;

    ●
    our
    ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals;

    ●
    our
    ability to advance product candidates into, and successfully complete, clinical trials;

    ●
    our
    ability to recruit and enroll suitable patients in our clinical trials;

13

    ●
    the
    timing or likelihood of the accomplishment of various scientific, clinical, regulatory, and other product development objectives;

    ●
    the
    pricing and reimbursement of our product candidates, if approved;

    ●
    the
    rate and degree of market acceptance of our product candidates, if approved;

    ●
    the
    implementation of our business model and strategic plans for our business, product candidates, and technology;

    ●
    the
    scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and technology;

    ●
    developments
    relating to our competitors and our industry;

    ●
    the
    development of major public health concerns and the future impact of such concerns on our clinical trials, business operations and
    funding requirements; and

    ●
    other
    risks and factors listed under “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024
    and elsewhere in this Report.

Given
the risks and uncertainties set forth in this Report, you are cautioned not to place undue reliance on such forward-looking statements.
The forward-looking statements contained in this Report are not guarantees of future performance and